mTORC1 is required to prevent cellular senescence.

Slides:

Advertisements

Similar presentations

(+++) Normal breast ATM (++) IDC ATM Lymph node metastasis negative positive P-value A B X200 C Vector ATM - WT.

Advertisements

c-Myc expression in response to pre-TCR stimulation.

Figure 4. Naturally occurring senescent cells from a HER2-expressing patient-derived xenograft secrete IL-6, which is required for tumor growth. A ) A.

Neal et al.Supplementary Figure S1

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition. B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition.

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI- 258) and its Therapeutic Implications Shalini S. Yadav, Jinyi.

Takashi Tanaka, Michelle A. Soriano, Michael J. Grusby Immunity

Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid–mediated transactivation is dispensable by Scott C. Kogan, Suk-hyun.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

DNA Damage-Mediated Induction of a Chemoresistant Niche

Atg7 deficiency has distinct consequences for tumor establishment and maintenance in BrafV600E-driven lung tumors and is associated with the emergence.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

DNA Damage-Mediated Induction of a Chemoresistant Niche

KRAS-induced chemoattractants mediate attraction of macrophages.

Pten deficiency induces strong stromal reaction with immune cell infiltration and promotes the development of invasive and metastatic pancreatic tumors.

In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.

Deletion of Crebbp in the GC cooperates with BCL2 deregulation to promote lymphomagenesis. Deletion of Crebbp in the GC cooperates with BCL2 deregulation.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Therapy-induced senescence of primary cells.

PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded skin. PEDF inhibits Wnt/T-cell factor/β-catenin signaling in resting and wounded.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Supplementary figure 1 A B Water (Control) Pre-alcohol Post-alcohol

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

FOXO3a phosphorylation and expression.

BME treatment increases granzyme B expression in NK 3.3 cells.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.

Quercetin induces apoptosis in P39 xenografts.

Effect of G9a on the expression of GSH synthesis enzymes.

Histopathology of anal tissue.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

CD4+ and CD8+ TILs express surface CD137.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

HMQ1611 inhibited breast tumor growth in mice.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant.

Effect of SPINDLIN1 protein on cancer cell proliferation and invasion.

Metabolite profiling of DFMO-treated ApcMin mouse tumors.

Model of minimal residual disease.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

In vivo effects of TTFields on intradermal tumors in mice.

P53-expressing tumor cells circumvent mitosis, express markers consistent with a G1-like state, and become senescent in response to continuous chemotherapeutic.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

MSCs elicit EMT, invasion of carcinoma cells, and increased tumor initiation of xenografts. MSCs elicit EMT, invasion of carcinoma cells, and increased.

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Volume 14, Issue 2, Pages (August 2008)

Presentation transcript:

mTORC1 is required to prevent cellular senescence. mTORC1 is required to prevent cellular senescence. A and B, syngeneic mice were injected with Eμ-Myc lymphoma cells (tumor #299), treated once daily with everolimus (E) after the development of overt malignancy, and sacrificed after 0, 2, 4, 7, and 11 days of therapy (n = 4 mice per group). A, sections from lymph nodes of untreated mice and mice sacrificed 2, 4, 7, and 11 days after chronic daily dosing with everolimus were stained with hematoxylin and eosin (H&E), SA-β-gal, anti-Gr1, and anti-F4/80. B, expression of phospho- (P-S15 p53) and total p53, p21, p19ARF, phospho- (P-p38MAPK) and total p38 MAPK, phospho- (P-RPS6), and total RPS6 and H3K9me3 in tumor lysates by Western blotting. Actin was used as a loading control. Full-length blots are presented in Supplementary Fig. S12. C, Four-week-old Eμ-Myc mice were treated with daily placebo (n = 4) or everolimus (n = 4) and sacrificed after 4 days. Splenic sections were stained with H&E (top), or SA-β-gal (bottom). Meaghan Wall et al. Cancer Discovery 2013;3:82-95 ©2013 by American Association for Cancer Research